{"prompt": "['2016N298481_02', 'CONFIDENTIAL', '205270', 'Algorithm B: Phase III-IV Liver Chemistry Increased Monitoring Algorithm with', 'Continued Therapy for ALT >3xULN but <8xULN', 'Must referto Liver Safety Required Actions and Follow up Assessments section in the Appendix', 'Continue Study Treatment and Monitor Liver Chemistry', 'Yes', 'No', 'No', 'ALT>5xULN', 'ALT <5xULN', 'Yes', 'Persistsfor', 'Persists for', 'Yes', 'Able to', '>2weeks', 'Yes', 'Ableto', '24 weeks', 'monitor', 'or other', 'monitor', 'or other', 'ALT25xULN', 'Yes', 'Yes', 'No', 'ALT >3xULN', 'weekly', 'stopping', 'Yes', 'weekly', 'Yes', 'stopping', 'but <8xULN', 'for 2', 'criteria', 'but <5xULN', 'for 24', 'criteria', '+bili <2xULN +', 'weeks', 'met', 'bili <2xULN +', 'weeks', 'met', 'no symptoms', 'no symptoms', 'No', 'Yes', 'No', 'Yes', 'Discontinue Study Treatment', 'A Mustrefer to Liver Safety Required Actions and Follow up Assessments section in the A ppendix', \"Reportas an SAE if possible Hy's Lawcase:ALTa3xULN and Bilirubina2xULN (>35% direct) or\", 'INR>1.5, if measured*', 'INR value not applicable to subjects on anticoagulants', 'Liver Safety Required Actions and Follow up Assessments Section can be found in', 'Section 12.6 (Appendix 6).', '8.2.', 'Withdrawal from the Study', 'Specific wording is included in the informed consent form which permits participants to', 'discontinue study treatment and study procedures, but states an expectation that follow up', 'information will always be required. Participants will agree to this at the time of', 'consenting.', 'Withdrawal of consent from the study is expected to be a rare occurrence. If a participant', 'expresses a wish to withdraw consent from the study, the investigator will review the', 'following contact options with the participant.', 'In-clinic and phone visits', 'Follow-up via medical records review and/or other treating physician', 'Follow-up via family member or other third party contact', 'If all of these options are refused, then no further study visits or study-related telephone', 'contacts will be conducted and the participant will be considered to have withdrawn', 'consent. The principal investigator will be required to document that all alternative', 'options have been reviewed with the participant.', '52']['2016N298481_02', 'CONFIDENTIAL', '205270', 'For these participants, information regarding vital status will continue to be collected', 'from available sources including those in the public domain based on accepted local laws', 'and regulations. Where permitted, a third party may be used to obtain information.', 'In rare cases if a participant has been discontinued from the study without discussing all', 'possible alternatives for follow-up the investigator may contact the participants to discuss', 'all of the alternative methods of follow-up described above.', 'Participants may withdraw from the study at any time at his/her own request, or may be', 'withdrawn at any time at the discretion of the investigator for safety, behavioral,', 'compliance or administrative reasons.', 'If the participant withdraws consent for disclosure of future information, the sponsor may', 'retain and continue to use any data collected before such a withdrawal of consent.', 'If a participant withdraws from the study, he/she may request destruction of any samples', 'taken and not tested, and the investigator must document this in the site study records.', 'Refer to the SoA (Section 2) for data to be collected at the time of study treatment', 'discontinuation and follow-up and for any further evaluations that need to be completed.', '8.3.', 'Lost to Follow Up', 'A participant will be considered lost to follow-up if he or she repeatedly fails to return for', 'scheduled visits and is unable to be contacted by the study site.', 'The following actions must be taken if a participant fails to return to the clinic for a', 'required study visit:', 'Investigators should make every effort to contact participants who are deemed', 'lost to follow-up and who have not withdrawn consent to follow-up contact', 'The site must attempt to contact the participant and reschedule the missed visit', 'as soon as possible and counsel the participant on the importance of maintaining', 'the assigned visit schedule and ascertain whether or not the participant wishes to', 'and/or should continue in the study.', 'Before a participant is deemed lost to follow up, the investigator or designee', 'must make every effort to regain contact with the participant (where possible,', 'telephone calls, medical records review, third-part follow-up and/ora certified', \"letter to the participant's last known mailing address or local equivalent\", \"methods). These contact attempts should be documented in the participant's\", 'medical record.', '9.', 'STUDY ASSESSMENTS AND PROCEDURES', 'Study procedures and their timing are summarized in the SoA (Section 2).', 'Protocol waivers or exemptions are not allowed with the exception of immediate', 'safety concerns.', '53']\n\n###\n\n", "completion": "END"}